• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

0.05%丙酸倍他米松在人体皮肤中的昼夜活性(体内研究)

Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo.

作者信息

Pershing L K, Corlett J L, Lambert L D, Poncelet C E

机构信息

Division of Dermatology, University of Utah School of Medicine, Salt Lake City.

出版信息

J Invest Dermatol. 1994 May;102(5):734-9. doi: 10.1111/1523-1747.ep12376062.

DOI:10.1111/1523-1747.ep12376062
PMID:8176255
Abstract

The influence of treatment duration, vehicle, and time of day of application on topical 0.05% betamethasone dipropionate uptake into human stratum corneum and the resulting skin-blanching response was investigated in human subjects. Drug uptake into stratum corneum and the resulting skin color changes measured with a chromameter demonstrate an equilibrium delay. Maximal drug uptake occurred at 2 h, whereas maximal skin color changes occurred 6 h after a single application. Extent of decreased skin color was dependent on vehicle, treatment duration, and time of day of application. Time of maximal decreased skin color occurred at midnight independent of vehicle, treatment duration, or time of day of application. This time of maximal drug activity coincides with the well-known time period of lowest circulating cortisol concentrations (2000-0400 h). Application of a single 2- or 6-h dose of the 0.05% cream at 1600 h produced more extensive and prolonged changes in skin color over 24 h than a 0900-h application in the same subject. These data demonstrate that the extent and duration of topical corticosteroid activity in human skin is influenced by vehicle, treatment duration, and time of day of application. The prolonged changes in skin color measured with a single dose applied at 1600 h suggest that a once-a-day dosing regimen in the late afternoon may be sufficient for dermatologic therapy. Elucidation of these circadian responses with topical corticosteroids may provide a rational basis for the future re-evaluation of the appropriate therapeutic regimen with this class of drugs in dermatologic medicine.

摘要

在人体受试者中,研究了治疗时长、赋形剂以及给药时间对局部应用0.05%丙酸倍他米松进入人体角质层以及由此产生的皮肤变白反应的影响。用色度计测量的药物进入角质层的情况以及由此产生的皮肤颜色变化显示存在平衡延迟。单次给药后,最大药物摄取在2小时出现,而最大皮肤颜色变化在6小时出现。皮肤颜色降低的程度取决于赋形剂、治疗时长以及给药时间。皮肤颜色最大降低的时间在午夜出现,与赋形剂、治疗时长或给药时间无关。这个最大药物活性时间与众所周知的循环皮质醇浓度最低的时间段(20:00 - 04:00)相吻合。在16:00给予单次2小时或6小时剂量的0.05%乳膏,与在同一受试者09:00给药相比,在24小时内产生更广泛且持续时间更长的皮肤颜色变化。这些数据表明,局部皮质类固醇在人体皮肤中的活性程度和持续时间受赋形剂、治疗时长和给药时间的影响。在16:00给予单剂量测量到的皮肤颜色持续变化表明,下午晚些时候每日一次的给药方案可能足以用于皮肤病治疗。阐明局部皮质类固醇的这些昼夜反应可能为未来重新评估这类药物在皮肤病医学中的适当治疗方案提供合理依据。

相似文献

1
Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo.0.05%丙酸倍他米松在人体皮肤中的昼夜活性(体内研究)
J Invest Dermatol. 1994 May;102(5):734-9. doi: 10.1111/1523-1747.ep12376062.
2
Topical 0.050% betamethasone dipropionate. Pharmacokinetic and pharmacodynamic dose-response studies in humans.外用0.050%丙酸倍他米松。人体药代动力学和药效学剂量反应研究。
Arch Dermatol. 1994 Jun;130(6):740-7. doi: 10.1001/archderm.130.6.740.
3
Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.利用皮肤中的药物含量和皮肤变白生物测定法测定市售制剂中丙酸倍他米松局部生物利用度的可行性。
Pharm Res. 1992 Jan;9(1):45-51. doi: 10.1023/a:1018975626210.
4
New approaches to assess topical corticosteroid bioequivalence: pharmacokinetic evaluation.
Int J Dermatol. 1992 Oct;31 Suppl 1:14-20. doi: 10.1111/j.1365-4362.1992.tb04007.x.
5
Blanching activities of betamethasone formulations. The effect of dosage form on topical drug availability.倍他米松制剂的皮肤变白活性。剂型对局部药物可用性的影响。
Arzneimittelforschung. 1990 May;40(5):618-21.
6
A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.一项比较研究,旨在评估使用卡泊三醇/倍他米松外用混悬液与0.05%丙酸倍他米松洗剂治疗的银屑病患者的表皮屏障完整性。
J Drugs Dermatol. 2017 Aug 1;16(8):747-752.
7
In vivo characterization of structural changes after topical application of glucocorticoids in healthy human skin.在健康人体皮肤表面应用糖皮质激素后的结构变化的体内特征。
J Biomed Opt. 2017 Jul 1;22(7):76018. doi: 10.1117/1.JBO.22.7.076018.
8
Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.使用人体皮肤变白试验对两种分别含有0.1%地奈德或0.05%卤米松的新型外用皮质类固醇乳膏进行效能分级。
Arzneimittelforschung. 1988 Dec;38(12):1840-3.
9
Evaluation of change in the skin concentration of tazarotene and betamethasone dipropionate based on drug-drug interaction for transdermal drug delivery in miniature pig.基于药物相互作用评估微型猪经皮给药时他扎罗汀和丙酸倍氯米松皮肤浓度的变化。
Xenobiotica. 2015 May;45(5):380-4. doi: 10.3109/00498254.2014.985762. Epub 2014 Nov 20.
10
Assessment of dermal bioavailability: predicting the input function for topical glucocorticoids using stratum corneum sampling.皮肤生物利用度评估:利用表皮角质层取样预测局部皮质类固醇的输入函数。
Drug Deliv Transl Res. 2022 Apr;12(4):851-861. doi: 10.1007/s13346-021-01064-8. Epub 2021 Oct 1.

引用本文的文献

1
Circadian Variation in Efficacy of Medications.药物疗效的昼夜节律变化。
Clin Pharmacol Ther. 2021 Jun;109(6):1457-1488. doi: 10.1002/cpt.2073. Epub 2020 Nov 29.
2
Biological Rhythms in the Skin.皮肤中的生物节律
Int J Mol Sci. 2016 May 24;17(6):801. doi: 10.3390/ijms17060801.
3
24-hour rhythm of aquaporin-3 function in the epidermis is regulated by molecular clocks.分子钟调控表皮层水通道蛋白-3 功能的 24 小时节律。
J Invest Dermatol. 2014 Jun;134(6):1636-1644. doi: 10.1038/jid.2014.13. Epub 2014 Jan 13.
4
A PAMPA assay as fast predictive model of passive human skin permeability of new synthesized corticosteroid C-21 esters.PAMPA 法作为预测新合成的皮质甾族化合物 C-21 酯类经皮渗透的快速体外模型。
Molecules. 2012 Jan 5;17(1):480-91. doi: 10.3390/molecules17010480.
5
[Classical topical therapy of psoriasis].[银屑病的经典局部治疗]
Hautarzt. 2006 Aug;57(8):666-71. doi: 10.1007/s00105-006-1186-8.
6
Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.对美国食品药品监督管理局(FDA)提议的用于局部用皮质类固醇生物等效性测试的中剂量-反应方法的评估。
Pharm Res. 1997 Mar;14(3):303-8. doi: 10.1023/a:1012089803281.